39 results about "Opioid withdrawal" patented technology

Methods and compositions are provided for treating individuals exhibiting opioid withdrawal symptoms with opioid, benzodiazepine and other drugs of abuse by administering an opioid receptor antagonist agent together with a respiratory stimulant to reverse the effects of opioid withdrawal symptoms, including respiratory depression, sedation, and hypotension. Methods and compositions are also provided for treating stimulant overdose with a benzodiazepine and beta-adrenergic blocking agent. Methods and compositions are also provided for treating concurrent stimulant and opioid overdose comprising administering to a patient in need thereof a benzodiazepine and an opioid antagonist. Methods and compositions are also provided for treating individuals exhibiting opioid withdrawal symptoms or prophy tactically treating individuals for opioid withdrawal symptoms from opioid, benzodiazepine and other drugs of abuse by administering an opioid receptor antagonist agent together with a respiratory stimulant to reverse the effects of withdrawal, including respiratory depression, sedation, and hypotension.

The present application includes mitragynine analogues of Formula la or lb, compositions comprising said compounds and uses thereof, for example for treating and managing pain, for treating neurological or psychiatric diseases and disorders, for example treating an opioid addiction or opioid withdrawal symptoms.

The present disclosure provides a method for using nalfurafine or nalmefene for activating JNK / PRDX6 to stimulate localized peroxide production that causes G-protein depalmitoylation and deactivation of kappa opioid receptors (KORs) in a subject; a method for using nalfurafine or nalmefene for inactivating kappa opioid receptors responsible for dysphoria during mu-opioid withdrawal in a subject; a method for using nalfurafine or nalmefene for promoting stress resilience in a subject recovering from polysubstance withdrawal; a method for using nalfurafine or nalmefene for inactivating kappa opioid receptor responsible for the dysphoria and psychotomimetic effects of kappa opioid agonists administered to a subject for the treatment of pruritus or for the promotion of diuresis; and a method for using nalfurafine or nalmefene in combination with a kappa opioid agonist for the treatment of neuropathic pain in a subject.